{
    "nctId": "NCT03503799",
    "briefTitle": "Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer",
    "officialTitle": "Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict\u00ae Gene Expression Testing - a Care Research Study",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1191,
    "primaryOutcomeMeasure": "Distant metastasis free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Informed consent\n2. Tested with EndoPredict within the previous 6 months before inclusion\n3. Age \u2265 18 years\n4. Patients with primary invasive breast cancer, Stage I/II\n5. ER-positive\n6. HER2-negative\n7. N0 or N1 (1-3 positive lymph nodes)\n8. T1 - T3\n\nExclusion Criteria:\n\n1. Inflammatory breast cancer\n2. Bilateral breast cancer\n3. Breast cancer in the last 10 years\n4. Other invasive malignancies in the last 5 years",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}